Clinical trial
Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide…
NCT00331175 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00331175 |
|---|---|
| Title | Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults |
| Official title | A Phase 1, Randomized, Placebo- And Positive Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Escalating Doses Of Intravenous Peptide YY3-36 In Otherwise Healthy Overweight Adult Subjects |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Obesity |
| Intervention type | Drug |
| Interventions | Peptide YY3-36 |
| Enrollment | 31 |
| Start date | Jul 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | May 29, 2006 |
| Last update posted | Dec 15, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: